Fiocruz said the measure was due to ‘low demand’
Without much fanfare, Brazil suspended production of the AstraZeneca vaccine against covid-19 in October last year. The information, however, gained more evidence this week, after posts published on social networks.
The immunizer was being made by the Oswaldo Cruz Foundation (Fiocruz). At the beginning of the coronavirus pandemic, the Jair Bolsonaro government entered into a partnership with AstraZeneca for the product to be developed in Brazil. In 2022, however, the Ministry of Health (MS) did not renew the contract.
read more:
Sought by Oeste, Fiocruz said that the suspension of production of the AstraZeneca vaccine was due to “low demand”. “At the moment, Bio-Manguinhos/Fiocruz is producing a new batch of active pharmaceutical ingredient, which will remain in stock”, said the foundation, in a note.
Fiocruz guaranteed that it continues to manufacture other vaccines for the MS National Immunization Program.
Two months after the act, considering the high risk of thrombosis, especially in women, the MS recommended viral vector immunizers — such as Janssen — only for people over 40 years old.
“This general coordination understands that it is pertinent to update the recommendations for the use of viral vector vaccines (Astrazeneca and Janssen), so that, in the population under 40 years old, vaccines against covid-19 from platforms that are not vector are preferably administered. viral”, highlighted Saúde.
West Magazine
Fiocruz said the measure was due to ‘low demand’
Without much fanfare, Brazil suspended production of the AstraZeneca vaccine against covid-19 in October last year. The information, however, gained more evidence this week, after posts published on social networks.
The immunizer was being made by the Oswaldo Cruz Foundation (Fiocruz). At the beginning of the coronavirus pandemic, the Jair Bolsonaro government entered into a partnership with AstraZeneca for the product to be developed in Brazil. In 2022, however, the Ministry of Health (MS) did not renew the contract.
read more:
Sought by Oeste, Fiocruz said that the suspension of production of the AstraZeneca vaccine was due to “low demand”. “At the moment, Bio-Manguinhos/Fiocruz is producing a new batch of active pharmaceutical ingredient, which will remain in stock”, said the foundation, in a note.
Fiocruz guaranteed that it continues to manufacture other vaccines for the MS National Immunization Program.
Two months after the act, considering the high risk of thrombosis, especially in women, the MS recommended viral vector immunizers — such as Janssen — only for people over 40 years old.
“This general coordination understands that it is pertinent to update the recommendations for the use of viral vector vaccines (Astrazeneca and Janssen), so that, in the population under 40 years old, vaccines against covid-19 from platforms that are not vector are preferably administered. viral”, highlighted Saúde.
West Magazine
